IPCI.F Stock Overview
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Intellipharmaceutics International Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.06 |
52 Week High | CA$0.14 |
52 Week Low | CA$0.0012 |
Beta | 0.38 |
1 Month Change | -26.29% |
3 Month Change | 8.11% |
1 Year Change | 20.00% |
3 Year Change | -74.14% |
5 Year Change | -69.26% |
Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
IPCI.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -55.6% | -1.5% | -3.2% |
1Y | 20.0% | 9.7% | 19.3% |
Return vs Industry: IPCI.F exceeded the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: IPCI.F matched the US Market which returned 19.3% over the past year.
Price Volatility
IPCI.F volatility | |
---|---|
IPCI.F Average Weekly Movement | 116.0% |
Pharmaceuticals Industry Average Movement | 9.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPCI.F's share price has been volatile over the past 3 months.
Volatility Over Time: IPCI.F's weekly volatility has decreased from 348% to 116% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 11 | Isa Odidi | www.intellipharmaceutics.com |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
Intellipharmaceutics International Inc. Fundamentals Summary
IPCI.F fundamental statistics | |
---|---|
Market cap | US$1.94m |
Earnings (TTM) | -US$3.17m |
Revenue (TTM) | US$904.95k |
2.1x
P/S Ratio-0.6x
P/E RatioIs IPCI.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPCI.F income statement (TTM) | |
---|---|
Revenue | US$904.95k |
Cost of Revenue | US$475.89k |
Gross Profit | US$429.06k |
Other Expenses | US$3.60m |
Earnings | -US$3.17m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.096 |
Gross Margin | 47.41% |
Net Profit Margin | -350.72% |
Debt/Equity Ratio | -16.9% |
How did IPCI.F perform over the long term?
See historical performance and comparison